SpringerLink
Log in

The Decision-Making Process for Prophylactic Central Neck Dissection in a Patient Presenting with an Indeterminate Thyroid Nodule on Cytology Assessment: Role of Preoperative Ultrasound and Molecular Marker Testing

  • Chapter
Thyroid Cancer

  • 1953 Accesses

Abstract

Nodular thyroid disease is a common clinical entity in the United States, with an estimated annual incidence of approximately 0.1 % per year. The clinical importance of nodular thyroid disease rests with the need to exclude nodules that are malignant. Although this goal can be achieved in most patients with conventional diagnostic techniques, including ultrasound (US) and fine-needle aspiration biopsy, conventional diagnostic methods cannot provide definitive diagnoses in many situations, and such cases are reported as “indeterminate”. Due to a lack of definitive diagnosis for indeterminate or suspicious thyroid nodules, the majority of these patients usually undergo diagnostic thyroidectomy to establish a histopathologic diagnosis. To detect nonpalpable lymph node metastases in patients undergoing surgical resection, a dedicated cervical US should be performed to evaluate the central and lateral neck compartments. The detection of lymph node metastases in this setting affords the opportunity to move forward with complete initial resection of all tumor tissue, that is, thyroidectomy and comprehensive compartment-oriented neck dissection. However, the role of prophylactic central neck dissection (CND) remains a contentious issue, because high-level evidence is lacking for such an approach. The clinical utilization of molecular markers as diagnostic preoperative adjuncts appears promising in differentiating benign from malignant thyroid nodules. This may enable the tailoring of more effective initial surgical management strategies in this patient population. However, the true impact of these adjuncts on determining the most optimal surgical extent from an oncologic standpoint has yet to be proven, as none of the currently commercially available molecular markers have been demonstrated to be clear, independent prognostic indicators and therefore should not impact the decision for prophylactic CND.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Yeh MW, Bauer AJ, Bernet V, Ferris RL, Loevner LA, Mandel SJ, et al. American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. Thyroid. 2014;25(1):3–14.

    Article  Google Scholar 

  2. Cibas ES, Ali SZ. The Bethesda system for reporting thyroid cytopathology. Am J Clin Pathol. 2009;132(5):658–65.

    Article  PubMed  Google Scholar 

  3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–214.

    Article  PubMed  Google Scholar 

  4. Carty SE, Cooper DS, Doherty GM, Duh QY, Kloos RT, Mandel SJ, et al. Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. Thyroid. 2009;19(11):1153–8.

    Article  PubMed  Google Scholar 

  5. Roy R, Kouniavsky G, Venkat R, Felger EA, Shiue Z, Schneider E, et al. The role of preoperative neck ultrasounds to assess lymph nodes in patients with suspicious or indeterminate thyroid nodules. J Surg Oncol. 2012;105(6):601–5.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Yoon JH, Kwak JY, Kim EK, Moon HJ, Kim MJ, Kim JY, et al. How to approach thyroid nodules with indeterminate cytology. Ann Surg Oncol. 2010;17(8):2147–55.

    Article  PubMed  Google Scholar 

  7. Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5(1):43–63.

    CAS  PubMed  Google Scholar 

  8. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, et al. Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. Surgery. 2003;134:946–54, discussion 54–5.

    Article  PubMed  Google Scholar 

  9. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22(11):1144–52.

    Article  PubMed  Google Scholar 

  10. Bardet S, Malville E, Rame JP, Babin E, Samama G, De Raucourt D, et al. Macroscopic lymph-node involvement and neck dissection predict lymph-node recurrence in papillary thyroid carcinoma. Eur J Endocrinol. 2008;158(4):551–60.

    Article  CAS  PubMed  Google Scholar 

  11. Cranshaw IM, Carnaille B. Micrometastases in thyroid cancer. An important finding? Surg Oncol. 2008;17(3):253–8.

    Article  PubMed  Google Scholar 

  12. Gemsenjager E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz PU. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg. 2003;197:182–90.

    Article  PubMed  Google Scholar 

  13. Hughes DT, White ML, Miller BS, Gauger PG, Burney RE, Doherty GM. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. Surgery. 2010;148:1100–6, discussion 006–7.

    Article  PubMed  Google Scholar 

  14. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L. Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin. Surgery. 2006;140(6):1000–5, discussion 5–7.

    Article  PubMed  Google Scholar 

  15. Qubain SW, Nakano S, Baba M, Takao S, Aikou T. Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. Surgery. 2002;131(3):249–56.

    Article  PubMed  Google Scholar 

  16. Lundgren CI, Hall P, Dickman PW, Zedenius J. Clinically significant prognostic factors for differentiated thyroid carcinoma: a population-based, nested case-control study. Cancer. 2006;106(3):524–31.

    Article  PubMed  Google Scholar 

  17. Zaydfudim V, Feurer ID, Griffin MR, Phay JE. The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. Surgery. 2008;144(6):1070–7, discussion 7–8.

    Article  PubMed  Google Scholar 

  18. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135(2):139–48.

    Article  PubMed  Google Scholar 

  19. Tisell LE, Nilsson B, Molne J, Hansson G, Fjalling M, Jansson S, et al. Improved survival of patients with papillary thyroid cancer after surgical microdissection. World J Surg. 1996;20(7):854–9.

    Article  CAS  PubMed  Google Scholar 

  20. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18(4):559–67, discussion 67–8.

    Article  CAS  PubMed  Google Scholar 

  21. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg. 2004;28(5):498–501.

    Article  PubMed  Google Scholar 

  22. Wang TS, Cheung K, Farrokhyar F, Roman SA, Sosa JA. A meta-analysis of the effect of prophylactic central compartment neck dissection on locoregional recurrence rates in patients with papillary thyroid cancer. Ann Surg Oncol. 2013;20(11):3477–83.

    Article  PubMed  Google Scholar 

  23. Shan CX, Zhang W, Jiang DZ, Zheng XM, Liu S, Qiu M. Routine central neck dissection in differentiated thyroid carcinoma: a systematic review and meta-analysis. Laryngoscope. 2012;122(4):797–804.

    Article  PubMed  Google Scholar 

  24. Kim E, Park JS, Son KR, Kim JH, Jeon SJ, Na DG. Preoperative diagnosis of cervical metastatic lymph nodes in papillary thyroid carcinoma: comparison of ultrasound, computed tomography, and combined ultrasound with computed tomography. Thyroid. 2008;18(4):411–8.

    Article  CAS  PubMed  Google Scholar 

  25. Nikiforov YE, Ohori NP, Hodak SP, Carty SE, LeBeau SO, Ferris RL, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96(11):3390–7.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Alexander EK, Kennedy GC, Baloch ZW, Cibas ES, Chudova D, Diggans J, et al. Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012;367(8):705–15.

    Article  CAS  PubMed  Google Scholar 

  27. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol. 2008;9(6):543–9.

    Article  CAS  PubMed  Google Scholar 

  28. Belfiore A, La Rosa GL. Fine-needle aspiration biopsy of the thyroid. Endocrinol Metab Clin N Am. 2001;30(2):361–400.

    Article  CAS  Google Scholar 

  29. Aragon Han P, Olson MT, Fazeli R, Prescott JD, Pai SI, Schneider EB, et al. The impact of molecular testing on the surgical management of patients with thyroid nodules. Ann Surg Oncol. 2014;21:1862–9.

    Article  PubMed  Google Scholar 

  30. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16(2):109–42.

    Article  PubMed  Google Scholar 

  31. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.

    Article  CAS  PubMed  Google Scholar 

  32. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. The American Thyroid Association (ATA) guidelines taskforce on thyroid nodules and differentiated thyroid cancer. Thyroid. 2015.

    Google Scholar 

  33. Carling T, Carty SE, Ciarleglio MM, Cooper DS, Doherty GM, Kim LT, et al. American Thyroid Association design and feasibility of a prospective randomized controlled trial of prophylactic central lymph node dissection for papillary thyroid carcinoma. Thyroid. 2012;22(3):237–44.

    Article  PubMed  Google Scholar 

  34. Zetoune T, Keutgen X, Buitrago D, Aldailami H, Shao H, Mazumdar M, et al. Prophylactic central neck dissection and local recurrence in papillary thyroid cancer: a meta-analysis. Ann Surg Oncol. 2010;17(12):3287–93.

    Article  PubMed  Google Scholar 

  35. Popadich A, Levin O, Lee JC, Smooke-Praw S, Ro K, Fazel M, et al. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. Surgery. 2011;150(6):1048–57.

    Article  PubMed  Google Scholar 

  36. Hartl DM, Mamelle E, Borget I, Leboulleux S, Mirghani H, Schlumberger M. Influence of prophylactic neck dissection on rate of retreatment for papillary thyroid carcinoma. World J Surg. 2013;37(8):1951–8.

    Article  PubMed  Google Scholar 

  37. Hartl DM, Leboulleux S, Al Ghuzlan A, Baudin E, Chami L, Schlumberger M, et al. Optimization of staging of the neck with prophylactic central and lateral neck dissection for papillary thyroid carcinoma. Ann Surg. 2012;255(4):777–83.

    Article  PubMed  Google Scholar 

  38. Wang TS, Evans DB, Fareau GG, Carroll T, Yen TW. Effect of prophylactic central compartment neck dissection on serum thyroglobulin and recommendations for adjuvant radioactive iodine in patients with differentiated thyroid cancer. Ann Surg Oncol. 2012;19(13):4217–22.

    Article  PubMed  Google Scholar 

  39. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lumbroso JD, Al Ghuzlan A, et al. Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. J Clin Endocrinol Metab. 2009;94:1162–7.

    Article  CAS  PubMed  Google Scholar 

  40. Laird AM, Gauger PG, Miller BS, Doherty GM. Evaluation of postoperative radioactive iodine scans in patients who underwent prophylactic central lymph node dissection. World J Surg. 2012;36(6):1268–73.

    Article  PubMed  Google Scholar 

  41. Roh JL, Park JY, Park CI. Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. Ann Surg. 2007;245:604–10.

    Article  PubMed Central  PubMed  Google Scholar 

  42. Lang BH, Wong KP, Wan KY, Lo CY. Impact of routine unilateral central neck dissection on preablative and postablative stimulated thyroglobulin levels after total thyroidectomy in papillary thyroid carcinoma. Ann Surg Oncol. 2012;19(1):60–7.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Chisholm EJ, Kulinskaya E, Tolley NS. Systematic review and meta-analysis of the adverse effects of thyroidectomy combined with central neck dissection as compared with thyroidectomy alone. Laryngoscope. 2009;119(6):1135–9.

    Article  PubMed  Google Scholar 

  44. Bardet S, Ciappuccini R, Quak E, Rame JP, Blanchard D, de Raucourt D, et al. Prognostic value of microscopic lymph node involvement in patients with papillary thyroid cancer. J Clin Endocrinol Metab. 2015;100(1):132–40.

    Article  CAS  PubMed  Google Scholar 

  45. Iyer NG, Shaha AR. Central compartment dissection for well differentiated thyroid cancer … and the band plays on. Curr Opin Otolaryngol Head Neck Surg. 2011;19(2):106–12.

    Article  PubMed  Google Scholar 

  46. **ng M, Alzahrani AS, Carson KA, Viola D, Elisei R, Bendlova B, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA. 2013;309(14):1493–501.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  47. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118(7):1764–73.

    Article  CAS  PubMed  Google Scholar 

  48. **ng M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321(1):86–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer. 2006;6(4):292–306.

    Article  CAS  PubMed  Google Scholar 

  50. Volante M, Rapa I, Gandhi M, Bussolati G, Giachino D, Papotti M, et al. RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab. 2009;94(12):4735–41.

    Article  CAS  PubMed  Google Scholar 

  51. Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, et al. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. J Clin Oncol. 2003;21(17):3226–35.

    Article  CAS  PubMed  Google Scholar 

  52. Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 2009;69(11):4885–93.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Sassolas G, Hafdi-Nejjari Z, Ferraro A, Decaussin-Petrucci M, Rousset B, Borson-Chazot F, et al. Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid. 2012;22(1):17–26.

    Article  CAS  PubMed  Google Scholar 

  54. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216–22.

    Article  PubMed  Google Scholar 

  55. Santoro M, Melillo RM, Fusco A. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. Eur J Endocrinol. 2006;155:645–53.

    Article  CAS  PubMed  Google Scholar 

  56. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:213–20.

    Article  CAS  PubMed  Google Scholar 

  57. Nikiforova MN, Biddinger PW, Caudill CM, Kroll TG, Nikiforov YE. PAX8-PPARgamma rearrangement in thyroid tumors: RT-PCR and immunohistochemical analyses. Am J Surg Pathol. 2002;26(8):1016–23.

    Article  PubMed  Google Scholar 

  58. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EK, Dorn 2nd GW, Tallini G, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318–26.

    Article  CAS  PubMed  Google Scholar 

  59. Armstrong MJ, Yang H, Yip L, Ohori NP, McCoy KL, Stang MT, et al. PAX8/PPARgamma rearrangement in thyroid nodules predicts follicular-pattern carcinomas, in particular the encapsulated follicular variant of papillary carcinoma. Thyroid. 2014;24(9):1369–74.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  60. Soares P, Celestino R, Melo M, Fonseca E, Sobrinho-Simoes M. Prognostic biomarkers in thyroid cancer. Virchows Arch. 2014;464:333–46.

    Article  CAS  PubMed  Google Scholar 

  61. Nikiforova MN, Wald AI, Roy S, Durso MB, Nikiforov YE. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J Clin Endocrinol Metab. 2013;98(11):E1852–60.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  62. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754–65.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  63. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603–10.

    Article  PubMed Central  PubMed  Google Scholar 

  64. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  65. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99(6):E1130–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  66. **ng M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–26.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

Download references

Conflicts of Interest Disclosures

All authors report no conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Head and Neck Endocrine Surgery, Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins University School of Medicine, 601 N. Caroline Street, 6th floor (6242), Baltimore, MD, 21287, USA

    Salem I. Noureldine MD & Ralph P. Tufano MD, MBA, FACS

Authors
  1. Salem I. Noureldine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ralph P. Tufano MD, MBA, FACS
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Salem I. Noureldine MD .

Editor information

Editors and Affiliations

  1. Johns Hopkins University, Baltimore, Maryland, USA

    David S. Cooper

  2. Department of Internal Medicine, University of Rome, Rome, Roma, Italy

    Cosimo Durante

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Noureldine, S.I., Tufano, R.P. (2016). The Decision-Making Process for Prophylactic Central Neck Dissection in a Patient Presenting with an Indeterminate Thyroid Nodule on Cytology Assessment: Role of Preoperative Ultrasound and Molecular Marker Testing. In: Cooper, D., Durante, C. (eds) Thyroid Cancer. Springer, Cham. https://doi.org/10.1007/978-3-319-22401-5_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22401-5_3

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22400-8

  • Online ISBN: 978-3-319-22401-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation